MAIA Biotechnology
MAIA
36 hedge funds and large institutions have $19.4M invested in MAIA Biotechnology in 2026 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 10 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
9% more funds holding
Funds holding: 33 → 36 (+3)
6% more capital invested
Capital invested by funds: $18.4M → $19.4M (+$1.03M)
0.57% more ownership
Funds ownership: 21.68% → 22.24% (+0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$552K |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$451K |
| 3 |
BlackRock
New York
|
+$365K |
| 4 |
BFG
Bleakley Financial Group
Fairfield,
New Jersey
|
+$241K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$191K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Solas Capital Management
Darien,
Connecticut
|
-$1.68M |
| 2 |
CCC
Cable Car Capital
San Francisco,
California
|
-$178K |
| 3 |
CCM
Corsair Capital Management
New York
|
-$140K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$40K |
| 5 |
RWM
Ritholtz Wealth Management
New York
|
-$32.3K |
MAIA Hedge Fund Activity: Q2 2026 in Review
36 of the 8,336 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q2 2026, worth a combined $19.4M — up 5.6% from $18.4M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new MAIA positions and 10 closed out — a net gain of 3 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $552K. The largest seller was Solas Capital Management, cutting an estimated $1.68M.
- 36 institutional investors held MAIA Biotechnology (MAIA) as of Q2 2026, up from 33 in Q1 2026.
- Funds reported $19.4M of MAIA Biotechnology stock for Q2 2026, up 5.6% quarter-over-quarter.
- 13 funds opened new MAIA Biotechnology positions in Q2 2026 and 10 closed out, a net change of +3 holders.
- The largest MAIA Biotechnology buyer in Q2 2026 was Renaissance Technologies, an estimated $552K added.
- The largest MAIA Biotechnology seller in Q2 2026 was Solas Capital Management, an estimated $1.68M sold.
Based on aggregated 13F filings for Q2 2026.